Further, in CLL cell lines HG3 and Mec-1, 72 h PRT382 treatment resulted in a decrease in global symmetric dimethyl arginine (SDMA) residues at doses as low as 100 nM, indicating potential efficacy for PRT382 against CLL cells (Fig. 7c). This evidence concerns the gene ATR and B-cell chronic lymphocytic leukemia.